Infection Prevention and Control Issues After Solid Organ Transplantation

  • David B. Banach
  • Maria Teresa A. Seville
  • Shimon Kusne


Infections are an important cause of morbidity and mortality in solid organ transplant recipients. Consequently, infection prevention is an essential component of any organ transplant program. Given their frequent and often prolonged contact with the healthcare system, solid organ transplant recipients are at high risk for healthcare-associated infections, including those caused by antibiotic-resistant organisms. In this chapter we review several different healthcare-associated infections of importance to transplant recipients, including those caused by bacterial, viral, and fungal organisms. We also describe infection prevention and control strategies applicable to this patient population. These practices focus on clinical interventions and environmental controls designed to prevent the spread of potentially pathogenic organisms in the healthcare setting. We also describe post-exposure interventions applicable to solid organ transplant recipients exposed to potential pathogens in order to reduce their risk of subsequent infection.


Infection control and prevention Healthcare-associated infections 



We would like to acknowledge the help of Sharon Krystofiak MS, MT (ASCP), CIC, from University of Pittsburgh Medical Center who assisted in writing the previous edition of this chapter.


  1. 1.
    Boyce JM, et al. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(RR-16):1–45, quiz CE1–4.Google Scholar
  2. 2.
    Tablan OC, et al. Guidelines for preventing health-care—associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53(RR-3):1–36.Google Scholar
  3. 3.
    Sehulster L, et al. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 2003;52(RR-10):1–42.Google Scholar
  4. 4.
    Siegel JD, et al. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007;35(10 Suppl 2):S165–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Siegel JD, et al. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10 Suppl 2):S65–164.PubMedCrossRefGoogle Scholar
  6. 6.
    Rutala WA, Weber DJ, the Healthcare Infection Control Practices Advisory Committee (HICPAC). Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008.Google Scholar
  7. 7.
    Blumberg EA, et al. Foreword: Guidelines 3. Am J Transplant. 2013;13 Suppl 4:1–2.PubMedCrossRefGoogle Scholar
  8. 8.
    Yokoe DS, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol. 2014;35 Suppl 2:S21–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Centers for Medicare and Medicaid Services. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates; payments for graduate medical education in certain emergency situations; changes to disclosure of physician ownership in hospitals and physician self-referral rules; updates to the long-term care prospective payment system; updates to certain IPPS-excluded hospitals; and collection of information regarding financial relationships between hospitals. Final rules. Fed Regist. 2008;73(161):48433-9084.Google Scholar
  10. 10.
    Occupational exposure to bloodborne pathogens—OSHA. Final rule. Fed Regist. 1991;56(235):64004-182.Google Scholar
  11. 11.
    Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Dudeck MA, et al. National Healthcare Safety Network report, data summary for 2013, device-associated module. Am J Infect Control. 2015;43(3):206–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Marschall J, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(7):753–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Rupp ME, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med. 2005;143(8):570–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Raad I, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997;127(4):267–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Safdar N, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis. Crit Care Med. 2014;42(7):1703–13.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Huang SS, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368(24):2255–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Climo MW, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368(6):533–42.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bolyard EA, et al. Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1998;19(6):407–63.Google Scholar
  20. 20.
    Avery RK, Michaels MG, AST Infectious Diseases Community of Practice. Strategies for safe living after solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):304–10.Google Scholar
  21. 21.
    Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol. 1989;5(2):131–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Kanamori H, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015;61(3):433–44.PubMedCrossRefGoogle Scholar
  23. 23.
    Hay RJ, Clayton YM, Goodley JM. Fungal aerobiology: how, when and where? J Hosp Infect. 1995;30(Suppl):352–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Anaissie EJ, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101(7):2542–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Iwen PC, et al. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol. 1994;15(5):303–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Garcia-Vidal C, et al. Environmental variables associated with an increased risk of invasive aspergillosis. Clin Microbiol Infect. 2014;20(11):O939–45.PubMedCrossRefGoogle Scholar
  27. 27.
    Wald A, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Pegues DA, et al. Cluster of cases of invasive aspergillosis in a transplant intensive care unit: evidence of person-to-person airborne transmission. Clin Infect Dis. 2002;34(3):412–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Streifel AJ. Clinical microbiology procedures handbook. Minneapolis: Department of Environmental Health and Safety, University of Minnesota; 1994.Google Scholar
  30. 30.
    Guidelines for Design and Construction of Health Care Facilities. The Facility Guidelines Institute, 2010 ed. 2010, Chicago, IL: American Society for Healthcare Engineering of the American Hospital Association.Google Scholar
  31. 31.
    Overberger PA, Wadowsky RM, Schaper MM. Evaluation of airborne particulates and fungi during hospital renovation. Am Ind Hyg Assoc J. 1995;56(7):706–12.PubMedCrossRefGoogle Scholar
  32. 32.
    Loo VG, et al. Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol. 1996;17(6):360–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Sarubbi Jr FA, et al. Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction. Am Rev Respir Dis. 1982;125(1):33–8.PubMedGoogle Scholar
  34. 34.
    Arnow PM, et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis. 1991;164(5):998–1002.PubMedCrossRefGoogle Scholar
  35. 35.
    Hagiwara D, et al. Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis. J Clin Microbiol. 2014;52(12):4202–9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med. 2002;162(13):1483–92.PubMedCrossRefGoogle Scholar
  37. 37.
    National Primary Drinking Water Regulations: Long Term 2 Enhanced Surface Water Treatment Rule, U.S. E.P. Agency, ed. Fed Regist. 2006:653–702.Google Scholar
  38. 38.
    Freije MR. Legionella control in healthcare facilities: a guide for minimizing risk. Indianapolis, IN: HC Information Resources; 1996.Google Scholar
  39. 39.
    Brundrett GW. Legionella and building services. Oxford England; Boston: Butterworth Heinemann; 1992, xvi, 410 p.Google Scholar
  40. 40.
    Mandel AS, et al. State regulation of hospital water temperature. Infect Control Hosp Epidemiol. 1993;14(11):642–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Blatt SP, et al. Nosocomial Legionnaires' disease: aspiration as a primary mode of disease acquisition. Am J Med. 1993;95(1):16–22.PubMedCrossRefGoogle Scholar
  42. 42.
    Yu VL. Could aspiration be the major mode of transmission for Legionella? Am J Med. 1993;95(1):13–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Stout JE, et al. Potable water as a cause of sporadic cases of community-acquired legionnaires' disease. N Engl J Med. 1992;326(3):151–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Liu Z, et al. Controlled evaluation of copper-silver ionization in eradicating Legionella pneumophila from a hospital water distribution system. J Infect Dis. 1994;169(4):919–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Sheffer PJ, et al. Efficacy of new point-of-use water filter for preventing exposure to Legionella and waterborne bacteria. Am J Infect Control. 2005;33(5 Suppl 1):S20–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Muraca PW, Yu VL, Goetz A. Disinfection of water distribution systems for legionella: a review of application procedures and methodologies. Infect Control Hosp Epidemiol. 1990;11(2):79–88.PubMedCrossRefGoogle Scholar
  47. 47.
    Stout JE, Yu VL, Muraca P. Isolation of Legionella pneumophila from the cold water of hospital ice machines: implications for origin and transmission of the organism. Infect Control. 1985;6(4):141–6.PubMedCrossRefGoogle Scholar
  48. 48.
    American Society of Heating, Refrigeration, and Air-Conditioning Engineers, Inc. BSR/ASHRAE Standard 188P Fifth Full Publication. Legionellosis: Risk Management for Building Water Systems. 2014 October 15, 2015; Available from:
  49. 49.
    Carratala J, et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis. 1995;20(5):1169–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 1990;161(1):41–4.PubMedCrossRefGoogle Scholar
  51. 51.
    Carratala J, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20(3):557–60. discussion 561-3.PubMedCrossRefGoogle Scholar
  52. 52.
    Khardori N, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990;12(6):997–1003.PubMedCrossRefGoogle Scholar
  53. 53.
    Maningo E, Watanakunakorn C. Xanthomonas maltophilia and Pseudomonas cepacia in lower respiratory tracts of patients in critical care units. J Infect. 1995;31(2):89–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Meyer KS, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993;119(5):353–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Zhong L, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors. J Infect. 2012;64(3):299–310.PubMedCrossRefGoogle Scholar
  56. 56.
    U.S. Centers for Disease Control and Prevention. Get Smart for Healthcare. July 27, 2015]; Available from:
  57. 57.
    Samuel R, et al. An outbreak of mediastinitis among heart transplant recipients apparently related to a change in the united network for organ sharing guidelines. Infect Control Hosp Epidemiol. 2002;23(7):377–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Singh N, et al. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 2006;27(2):122–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Paterson DL, et al. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation. 2003;75(2):194–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Muto CA, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol. 2003;24(5):362–86.PubMedCrossRefGoogle Scholar
  61. 61.
    U.S. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep. 2009;58(10):256–60.Google Scholar
  62. 62.
    From the Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin—United States, 1989–1993. JAMA. 1993;270(15):1796.Google Scholar
  63. 63.
    Hidron AI, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008;29(11):996–1011.PubMedCrossRefGoogle Scholar
  64. 64.
    Moellering Jr RC. Emergence of Enterococcus as a significant pathogen. Clin Infect Dis. 1992;14(6):1173–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Malathum K, Murray BE. Vancomycin-resistant enterococci: recent advances in genetics, epidemiology and therapeutic options. Drug Resist Updat. 1999;2(4):224–43.PubMedCrossRefGoogle Scholar
  66. 66.
    Edmond MB, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995;20(5):1126–33.PubMedCrossRefGoogle Scholar
  67. 67.
    Murray BE. What can we do about vancomycin-resistant enterococci? Clin Infect Dis. 1995;20(5):1134–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Shay DK, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172(4):993–1000.PubMedCrossRefGoogle Scholar
  69. 69.
    Wells CL, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis. 1995;21(1):45–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Donskey CJ, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343(26):1925–32.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Fridkin SK, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med. 2001;135(3):175–83.PubMedCrossRefGoogle Scholar
  72. 72.
    Rhinehart E, et al. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med. 1990;323(26):1814–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Boyce JM, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol. 1994;32(5):1148–53.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Livornese Jr LL, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med. 1992;117(2):112–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Linden PK, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 1996;22(4):663–70.PubMedCrossRefGoogle Scholar
  76. 76.
    McNeil SA, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.PubMedCrossRefGoogle Scholar
  77. 77.
    Ziakas PD, et al. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014;14(8):1887–94.PubMedCrossRefGoogle Scholar
  78. 78.
    Preventing the Spread of Vancomycin Resistance—A Report from the Hospital Infection Control Practices Advisory Committee prepared by the Subcommittee on Prevention and Control of Antimicrobial-Resistant Microorganisms in Hospitals; comment period and public meeting—CDC. Notice. Fed Regist. 1994;59(94):25758–63.Google Scholar
  79. 79.
    Quale J, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis. 1996;23(5):1020–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Montecalvo MA, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med. 1999;131(4):269–72.PubMedCrossRefGoogle Scholar
  81. 81.
    Karanfil LV, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol. 1992;13(4):195–200.PubMedCrossRefGoogle Scholar
  82. 82.
    Morris Jr JG, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med. 1995;123(4):250–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Sievert DM, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46(5):668–74.PubMedCrossRefGoogle Scholar
  84. 84.
    Limbago BM, et al. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol. 2014;52(3):998–1002.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Introduction to CDC’s guidelines for prevention of intravascular infections. NITA. 1982;5(1):39–50.Google Scholar
  86. 86.
    Bert F, et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis. 2000;31(5):1295–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Florescu DF, et al. Staphylococcus aureus infections after liver transplantation. Infection. 2012;40(3):263–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Singh N, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis. 2000;30(2):322–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Altman DR, et al. Transmission of methicillin-resistant Staphylococcus aureus via deceased donor liver transplantation confirmed by whole genome sequencing. Am J Transplant. 2014;14(11):2640–4.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Calfee DP, et al. Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35 Suppl 2:S108–32.PubMedCrossRefGoogle Scholar
  91. 91.
    D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol. 2004;25(10):842–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Lockhart SR, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol. 2007;45(10):3352–9.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    U.S. Centers for Disease Control and Prevention. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb Mortal Wkly Rep. 2004;53(45):1063–6.Google Scholar
  94. 94.
    Marchaim D, et al. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother. 2008;52(4):1413–8.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913–20.PubMedCrossRefGoogle Scholar
  96. 96.
    Thomson KS, Smith Moland E. Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2000;2(10):1225–35.PubMedCrossRefGoogle Scholar
  97. 97.
    Bratu S, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165(12):1430–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Cai JC, et al. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother. 2008;52(6):2014–8.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    U.S. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62(9):165–70.Google Scholar
  100. 100.
    Kalpoe JS, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18(4):468–74.PubMedCrossRefGoogle Scholar
  101. 101.
    Navon-Venezia S, et al. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50(9):3098–101.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Schwaber MJ, et al. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49(5): 2137–9.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Endimiani A, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother. 2008;52(7):2680–2.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.PubMedCrossRefGoogle Scholar
  105. 105.
    Patel G, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–106.PubMedCrossRefGoogle Scholar
  106. 106.
    Bennett JW, et al. KPC-2-producing Enterobacter cloacae and Pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother. 2009;53(1):292–4.PubMedCrossRefGoogle Scholar
  107. 107.
    Tenover FC, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis. 2006;12(8):1209–13.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Woodford N, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother. 2004;48(12):4793–9.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Samore MH. Epidemiology of nosocomial Clostridium difficile infection. Compr Ther. 1993;19(4):151–6.PubMedGoogle Scholar
  110. 110.
    Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant. 2008;13(6):592–600.PubMedCrossRefGoogle Scholar
  111. 111.
    Lessa FC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.PubMedCrossRefGoogle Scholar
  112. 112.
    U.S. Centers for Disease Control and Prevention. Surveillance for community-associated Clostridium difficile—Connecticut, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(13):340–3.Google Scholar
  113. 113.
    Muto CA, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26(3):273–80.PubMedCrossRefGoogle Scholar
  114. 114.
    Pepin J, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.PubMedCrossRefGoogle Scholar
  115. 115.
    Brown E, et al. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol. 1990;11(6):283–90.PubMedCrossRefGoogle Scholar
  116. 116.
    Deshpande A, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68(9):1951–61.PubMedCrossRefGoogle Scholar
  117. 117.
    McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162(3):678–84.PubMedCrossRefGoogle Scholar
  118. 118.
    McFarland LV, et al. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun. 1991;59(7):2456–62.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Boutros M, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation. 2012;93(10):1051–7.PubMedCrossRefGoogle Scholar
  120. 120.
    McFarland LV, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320(4):204–10.PubMedCrossRefGoogle Scholar
  121. 121.
    Clabots CR, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992;166(3):561–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Johnson S, et al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336(8707):97–100.PubMedCrossRefGoogle Scholar
  123. 123.
    Kim KH, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143(1):42–50.PubMedCrossRefGoogle Scholar
  124. 124.
    Dubberke ER, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol. 2014;35(6):628–45.PubMedCrossRefGoogle Scholar
  125. 125.
    Struelens MJ, et al. Control of nosocomial transmission of Clostridium difficile based on sporadic case surveillance. Am J Med. 1991;91(3B):138S–44.PubMedCrossRefGoogle Scholar
  126. 126.
    Brooks SE, et al. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol. 1992;13(2):98–103.PubMedCrossRefGoogle Scholar
  127. 127.
    Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.PubMedCrossRefGoogle Scholar
  128. 128.
    Zar FA, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–7.PubMedCrossRefGoogle Scholar
  129. 129.
    van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–15.PubMedCrossRefGoogle Scholar
  130. 130.
    Dallal RM, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363–72.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Theunissen C, et al. Clostridium difficile colitis in cystic fibrosis patients with and without lung transplantation. Transpl Infect Dis. 2008;10(4):240–4.PubMedCrossRefGoogle Scholar
  132. 132.
    Gellad ZF, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis. 2007;9(4):276–80.PubMedCrossRefGoogle Scholar
  133. 133.
    Len O, et al. Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transpl Int. 2012;25(12):1275–81.PubMedCrossRefGoogle Scholar
  134. 134.
    U.S. Centers for Disease Control and Prevention. Trends in tuberculosis incidence—United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):245–50.Google Scholar
  135. 135.
    Scott C, et al. Tuberculosis trends—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(10):265–9.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Jasmer RM, et al. Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection and transmission. Int J Tuberc Lung Dis. 1997;1(6):536–41.PubMedGoogle Scholar
  137. 137.
    Wada, S, Kusne S, Fung J, Rakela J. Foreign born is the most important risk factor for tuberculosis in adult liver transplant recipients. In 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996. New Orleans, LA.Google Scholar
  138. 138.
    U.S. Centers for Disease Control and Prevention, Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55(11):301–5.Google Scholar
  139. 139.
    Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 2006;55(43):1176.Google Scholar
  140. 140.
    U.S. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2011. 2012 July 27, 2015]; Available from:
  141. 141.
    Centers for Disease Control and Prevention. Extensively drug-resistant tuberculosis—United States, 1993–2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):250–3.Google Scholar
  142. 142.
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.PubMedCrossRefGoogle Scholar
  143. 143.
    U.S. Centers for Disease Control and Prevention. Transplantation-transmitted tuberculosis—Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep. 2008;57(13):333–6.Google Scholar
  144. 144.
    Jereb JA, et al. Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis. 1993;168(5):1219–24.PubMedCrossRefGoogle Scholar
  145. 145.
    Jensen PA, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54(RR-17):1–141.Google Scholar
  146. 146.
    Gitterman S. Revised device labeling for the Cepheid Xpert MTB/RIF assay for detecting Mycobacterium tuberculosis. MMWR Morb Mortal Wkly Rep. 2015;64(7):193.Google Scholar
  147. 147.
    U.S. Centers for Disease Control and Prevention. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use—United States, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(41):821–7.Google Scholar
  148. 148.
    Slovis BS, Plitman JD, Haas DW. The case against anergy testing as a routine adjunct to tuberculin skin testing. JAMA. 2000;283(15):2003–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Pai M, Riley LW, Colford Jr JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4(12):761–76.PubMedCrossRefGoogle Scholar
  150. 150.
    Mazurek GH, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54(RR-15): 49–55.Google Scholar
  151. 151.
    From the Centers for Disease Control and Prevention. Update: Nucleic acid amplification tests for tuberculosis. JAMA. 2000;284(7):826.Google Scholar
  152. 152.
    Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep. 1992;41(RR-11):61–71.Google Scholar
  153. 153.
    Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy. 2002;22(6):701–4.PubMedCrossRefGoogle Scholar
  154. 154.
    The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 1996;45(RR-4):1–18.Google Scholar
  155. 155.
    Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1–51.Google Scholar
  156. 156.
    U.S. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48): 1650–3.Google Scholar
  157. 157.
    U.S. Centers for Disease Control and Prevention. Severe isoniazid-associated hepatitis—New York, 1991–1993. MMWR Morb Mortal Wkly Rep. 1993;42(28):545–7.Google Scholar
  158. 158.
    Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection—New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(15):289–91.Google Scholar
  159. 159.
    Chenhsu RY, et al. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother. 2000; 34(1):27–31.PubMedCrossRefGoogle Scholar
  160. 160.
    Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med. 1990;88(1):77–80.PubMedCrossRefGoogle Scholar
  161. 161.
    Sawyer MH, et al. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis. 1994;169(1): 91–4.PubMedCrossRefGoogle Scholar
  162. 162.
    Kusne S, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation. 1995;60(6):619–21.PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Gershon AA, LaRussa P, Steinberg S. The varicella vaccine. Clinical trials in immunocompromised individuals. Infect Dis Clin North Am. 1996;10(3):583–94.PubMedCrossRefGoogle Scholar
  164. 164.
    Marin M., et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40.Google Scholar
  165. 165.
    Broyer M, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99(1):35–9.PubMedCrossRefGoogle Scholar
  166. 166.
    Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant. 2006;10(1):78–82.PubMedCrossRefGoogle Scholar
  167. 167.
    Varivax [package insert]. 2008, Merck & Co.: Whitehouse Stagion, NJ.Google Scholar
  168. 168.
    Brunell PA, Argaw T. Chickenpox attributable to a vaccine virus contracted from a vaccine with zoster. Pediatrics. 2000;106(2), E28.PubMedCrossRefGoogle Scholar
  169. 169.
    Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996;45(RR-11):1–36.Google Scholar
  170. 170.
    U.S. Centers for Disease Control and Prevention. Updated recommendations for use of VariZIG—United States, 2013. MMWR Morb Mortal Wkly Rep. 2013;62(28):574–6.Google Scholar
  171. 171.
    Pandya A, et al. Varicella-zoster infection in pediatric solid-organ transplant recipients: a hospital-based study in the prevaricella vaccine era. Pediatr Transplant. 2001;5(3):153–9.PubMedCrossRefGoogle Scholar
  172. 172.
    Goldstein SL, et al. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol. 2000;14(4):305–8.PubMedCrossRefGoogle Scholar
  173. 173.
    American Academy of Pediatrics Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics. 1993;91(3):674–6.Google Scholar
  174. 174.
    Asano Y, et al. Postexposure prophylaxis of varicella in family contact by oral acyclovir. Pediatrics. 1993;92(2):219–22.PubMedGoogle Scholar
  175. 175.
    Haiduven D, Stevens DA, Hench C. Postexposure varicella management: further comments. Infect Control Hosp Epidemiol. 1994;15(12):740–1.PubMedCrossRefGoogle Scholar
  176. 176.
    Lund J. Varicella zoster virus in the health care setting: risk and management. AAOHN J. 1993;41(8):369–73.PubMedGoogle Scholar
  177. 177.
    Tennenberg AM, et al. Varicella vaccination for healthcare workers at a university hospital: an analysis of costs and benefits. Infect Control Hosp Epidemiol. 1997;18(6):405–11.PubMedCrossRefGoogle Scholar
  178. 178.
    Weber DJ, Rutala WA, Hamilton H. Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol. 1996;17(10):694–705.PubMedCrossRefGoogle Scholar
  179. 179.
    Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102(3A):31–6. discussion 42–3.PubMedCrossRefGoogle Scholar
  180. 180.
    Billings JL, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):559–66.PubMedCrossRefGoogle Scholar
  181. 181.
    Vilchez R, et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation. 2002;73(7):1075–8.PubMedCrossRefGoogle Scholar
  182. 182.
    Choudhary ML, et al. Comparison of the conventional multiplex RT-PCR, real time RT-PCR and Luminex xTAG(R) RVP fast assay for the detection of respiratory viruses. 2015. J Med Virol.Google Scholar
  183. 183.
    Tran TT, et al. Lower respiratory tract viral infections in pediatric abdominal organ transplant recipients: a single hospital inpatient cohort study. Pediatr Transplant. 2013;17(5):461–5.PubMedCrossRefGoogle Scholar
  184. 184.
    McIntosh K, Halonen P, Ruuskanen O. Report of a workshop on respiratory viral infections: epidemiology, diagnosis, treatment, and prevention. Clin Infect Dis. 1993;16(1):151–64.PubMedCrossRefGoogle Scholar
  185. 185.
    U.S. Centers for Disease Control and Prevention. Brief report: respiratory syncytial virus activity—United States, 2004–2005. MMWR Morb Mortal Wkly Rep. 2005;54(49):1259–60.Google Scholar
  186. 186.
    Centers for Disease Control and Prevention. Brief report: respiratory syncytial virus activity—United States, July 2006–November 2007. MMWR Morb Mortal Wkly Rep. 2007;56(48):1263–5.Google Scholar
  187. 187.
    Hall CB, Douglas Jr RG. Nosocomial respiratory syncytial viral infections. Should gowns and masks be used? Am J Dis Child. 1981;135(6):512–5.PubMedCrossRefGoogle Scholar
  188. 188.
    Hall CB, Douglas Jr RG, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976;89(1):11–5.PubMedCrossRefGoogle Scholar
  189. 189.
    Wright SA, Bieluch VM. Selected nosocomial viral infections. Heart Lung. 1993;22(2):183–7.PubMedGoogle Scholar
  190. 190.
    Madeley CR. Viral infections in children's wards—how well do we manage them? J Hosp Infect. 1995;30(Suppl):163–71.PubMedCrossRefGoogle Scholar
  191. 191.
    Leclair JM, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med. 1987;317(6):329–34.PubMedCrossRefGoogle Scholar
  192. 192.
    Englund JA, et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988;109(3):203–8.PubMedCrossRefGoogle Scholar
  193. 193.
    Pohl C, et al. Respiratory syncytial virus infections in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):166–9.PubMedCrossRefGoogle Scholar
  194. 194.
    Miller RB, Chavers BM. Respiratory syncytial virus infections in pediatric renal transplant recipients. Pediatr Nephrol. 1996;10(2):213–5.PubMedCrossRefGoogle Scholar
  195. 195.
    Krinzman S, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant. 1998;17(2):202–10.PubMedGoogle Scholar
  196. 196.
    Sparrelid E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19(9):905–8.PubMedCrossRefGoogle Scholar
  197. 197.
    U.S. Centers for Disease Control and Prevention. Brief report: respiratory syncytial virus activity—United States, 2005–2006. MMWR Morb Mortal Wkly Rep. 2006;55(47):1277–9.Google Scholar
  198. 198.
    Michaels MG, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009;13(4):451–6.PubMedCrossRefGoogle Scholar
  199. 199.
    Matthey S, et al. Rapid detection of respiratory viruses by shell vial culture and direct staining by using pooled and individual monoclonal antibodies. J Clin Microbiol. 1992;30(3):540–4.PubMedPubMedCentralGoogle Scholar
  200. 200.
    Rabalais GP, et al. Rapid diagnosis of respiratory viral infections by using a shell vial assay and monoclonal antibody pool. J Clin Microbiol. 1992;30(6):1505–8.PubMedPubMedCentralGoogle Scholar
  201. 201.
    van Elden LJ, et al. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis. 2002;34(2):177–83.PubMedCrossRefGoogle Scholar
  202. 202.
    Vilchez RA, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2(3):287–91.PubMedCrossRefGoogle Scholar
  203. 203.
    Vilchez RA, Fung JJ, Kusne S. Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: a case report and review of the literature. Transplantation. 2000;70(3):543–5.PubMedCrossRefGoogle Scholar
  204. 204.
    Kumar D, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–6.PubMedPubMedCentralCrossRefGoogle Scholar
  205. 205.
    Lindley MC, et al. Influenza vaccination performance measurement among acute care hospital-based health care personnel—United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(37):812–5.PubMedPubMedCentralGoogle Scholar
  206. 206.
    Grohskopf LA, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)—United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(32):691–7.PubMedPubMedCentralGoogle Scholar
  207. 207.
    Brummitt CF, et al. Nosocomial adenovirus infections: molecular epidemiology of an outbreak due to adenovirus 3a. J Infect Dis. 1988;158(2):423–32.PubMedCrossRefGoogle Scholar
  208. 208.
    Vilchez RA, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant. 2003;3(2):116–20.PubMedCrossRefGoogle Scholar
  209. 209.
    Ruuskanen O. Respiratory syncytial virus—is it preventable? J Hosp Infect. 1995;30(Suppl):494–7.PubMedCrossRefGoogle Scholar
  210. 210.
    Rao GG. Control of outbreaks of viral diarrhoea in hospitals—a practical approach. J Hosp Infect. 1995;30(1):1–6.PubMedCrossRefGoogle Scholar
  211. 211.
    Ansari SA, Springthorpe VS, Sattar SA. Survival and vehicular spread of human rotaviruses: possible relation to seasonality of outbreaks. Rev Infect Dis. 1991;13(3):448–61.PubMedCrossRefGoogle Scholar
  212. 212.
    Pacini DL, et al. Nosocomial rotaviral diarrhea: pattern of spread on wards in a children's hospital. J Med Virol. 1987;23(4):359–66.PubMedCrossRefGoogle Scholar
  213. 213.
    Evans AS. Viral infections in humans, epidemiology and control. 3rd ed. New York: Plenum Publishing; 1991.Google Scholar
  214. 214.
    Yin Y, et al. Rotavirus in organ transplantation: drug-virus-host interactions. Am J Transplant. 2015;15(3):585–93.PubMedCrossRefGoogle Scholar
  215. 215.
    Adeyi OA, et al. Rotavirus infection in adult small intestine allografts: a clinicopathological study of a cohort of 23 patients. Am J Transplant. 2010;10(12):2683–9.PubMedCrossRefGoogle Scholar
  216. 216.
    LeBaron CW, et al. Viral agents of gastroenteritis. Public health importance and outbreak management. MMWR Recomm Rep. 1990;39(RR-5):1–24.Google Scholar
  217. 217.
    Fitts SW, et al. Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients. Clin Transplant. 1995;9(3 Pt 1):201–4.PubMedGoogle Scholar
  218. 218.
    Rogers M, et al. Rotavirus outbreak on a pediatric oncology floor: possible association with toys. Am J Infect Control. 2000;28(5):378–80.PubMedCrossRefGoogle Scholar
  219. 219.
    Parashar UD, et al. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-12):1–13.Google Scholar
  220. 220.
    U.S. Centers for Disease Control and Prevention. Postmarketing monitoring of intussusception after RotaTeq vaccination—United States, February 1, 2006–February 15, 2007. MMWR Morb Mortal Wkly Rep. 2007;56(10):218–22.Google Scholar
  221. 221.
    Parashar UD, et al. Value of post-licensure data on benefits and risks of vaccination to inform vaccine policy: The example of rotavirus vaccines. 2015. Vaccine.Google Scholar
  222. 222.
    U.S. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity—United States, November 2007–May 2008. MMWR Morb Mortal Wkly Rep. 2008;57(25):697–700.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • David B. Banach
    • 1
  • Maria Teresa A. Seville
    • 2
  • Shimon Kusne
    • 2
  1. 1.Department of MedicineYale School of MedicineNew HavenUSA
  2. 2.Infection Prevention and Control, Infectious DiseasesMayo Clinic HospitalPhoenixUSA

Personalised recommendations